Establishment and characterization of NCC‑DMM1‑C1, a novel patient‑derived cell line of desmoplastic malignant pleural mesothelioma

Noguchi,Rei; Yoshimatsu,Yuki; Ono,Takuya; Sei,Akane; Motoi,Noriko; Yatabe,Yasushi; Yoshida,Yukihiro; Watanabe,Shunichi; Kondo,Tadashi

doi:10.3892/ol.2021.13182

Establishment and characterization of NCC‑DMM1‑C1, a novel patient‑derived cell line of desmoplastic malignant pleural mesothelioma

Authors:
- Rei Noguchi
- Yuki Yoshimatsu
- Takuya Ono
- Akane Sei
- Noriko Motoi
- Yasushi Yatabe
- Yukihiro Yoshida
- Shunichi Watanabe
- Tadashi Kondo
View Affiliations

Affiliations: Division of Rare Cancer Research, National Cancer Center Research Institute, Chuo‑ku, Tokyo 104‑0045, Japan, Department of Pathology and Clinical Laboratories, National Cancer Center Hospital, Chuo‑ku, Tokyo 104‑0045, Japan, Department of Thoracic Surgery, National Cancer Center Hospital, Chuo‑ku, Tokyo 104‑0045, Japan
Published online on: December 27, 2021 https://doi.org/10.3892/ol.2021.13182
Article Number: 64
Copyright: © Noguchi et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Desmoplastic malignant pleural mesothelioma (DMM) is a rare histological variant of malignant pleural mesothelioma, which is a highly aggressive neoplasm of the mesothelium. DMM is associated with distant metastases and short survival. Effective treatments for DMM are not established and the development of histotype‑tailored treatments is difficult due to the rarity of the disease. Although patient‑derived cancer models are crucial tools for the development of novel therapeutics, they are difficult to obtain for DMM; no DMM cell lines or xenografts are available from public biobanks and only two cell lines have been reported. Thus, the present study aimed to establish a novel cell line of DMM as a resource for drug screening. A cell line of DMM was established, designated as NCC‑DMM1‑C1, using surgically resected tumor tissues from a 73‑year‑old male patient with DMM. Characteristics of NCC‑DMM1‑C1 cells were examined, such as growth, spheroid formation and invasion capability. Drug targets and anti‑cancer drugs with anti‑proliferative efficacy were examined using a comprehensive kinase activity assay and drug screening of 213 anti‑cancer agents, respectively. NCC‑DMM1‑C1 exhibited fast growth, spheroid formation and invasion capability, suggesting that the NCC‑DMM1‑C1 cells retained the aggressive features of DMM. NCC‑DMM1‑C1 cells and the tumor tissue shared common activity profiles of kinases, which included FES, Wee1, platelet‑derived growth factor receptor‑β and Src. The drug screening revealed that bortezomib, fostamatinib, gemcitabine, homoharringtonine and vinorelbine had anti‑proliferative effects, which have not been previously reported for DMM. It was concluded that NCC‑DMM1‑C1 cells may be a useful tool for the study of DMM.

View Figures

View References

1	Gibbs AR and Thunnissen FB: Histological typing of lung and pleural tumours: Third edition. J Clin Pathol. 54:498–499. 2001. View Article : Google Scholar : PubMed/NCBI
2	Galateau-Salle F, Churg A, Roggli V and Travis WD; World Health Organization Committee for Tumors of the Pleura, : The 2015 World Health Organization classification of tumors of the pleura: Advances since the 2004 classification. J Thorac Oncol. 11:142–154. 2016. View Article : Google Scholar : PubMed/NCBI
3	Hashimoto K, Okuma Y, Hosomi Y and Hishima T: Malignant mesothelioma of the pleura with desmoplastic histology: A case series and literature review. BMC Cancer. 16:7182016. View Article : Google Scholar : PubMed/NCBI
4	Leung AN, Müller NL and Miller RR: CT in differential diagnosis of diffuse pleural disease. AJR Am J Roentgenol. 154:487–492. 1990. View Article : Google Scholar : PubMed/NCBI
5	Kawashima A and Libshitz HI: Malignant pleural mesothelioma: CT manifestations in 50 cases. AJR Am J Roentgenol. 155:965–969. 1990. View Article : Google Scholar : PubMed/NCBI
6	Wang ZJ, Reddy GP, Gotway MB, Higgins CB, Jablons DM, Ramaswamy M, Hawkins RA and Webb WR: Malignant pleural mesothelioma: Evaluation with CT, MR imaging, and PET. Radiographics. 24:105–119. 2004. View Article : Google Scholar : PubMed/NCBI
7	Vogelzang NJ, Rusthoven JJ, Symanowski J, Denham C, Kaukel E, Ruffie P, Gatzemeier U, Boyer M, Emri S, Manegold C, et al: Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol. 21:2636–2644. 2003. View Article : Google Scholar : PubMed/NCBI
8	Zauderer MG, Kass SL, Woo K, Sima CS, Ginsberg MS and Krug LM: Vinorelbine and gemcitabine as second- or third-line therapy for malignant pleural mesothelioma. Lung Cancer. 84:271–274. 2014. View Article : Google Scholar : PubMed/NCBI
9	Christoph DC and Eberhardt WE: Systemic treatment of malignant pleural mesothelioma: New agents in clinical trials raise hope of relevant improvements. Curr Opin Oncol. 26:171–181. 2014. View Article : Google Scholar : PubMed/NCBI
10	Sharma SV, Haber DA and Settleman J: Cell line-based platforms to evaluate the therapeutic efficacy of candidate anticancer agents. Nat Rev Cancer. 10:241–253. 2010. View Article : Google Scholar : PubMed/NCBI
11	Barretina J, Caponigro G, Stransky N, Venkatesan K, Margolin AA, Kim S, Wilson CJ, Lehár J, Kryukov GV, Sonkin D, et al: The cancer cell line encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature. 483:603–607. 2012. View Article : Google Scholar : PubMed/NCBI
12	Iorio F, Knijnenburg TA, Vis DJ, Bignell GR, Menden MP, Schubert M, Aben N, Gonçalves E, Barthorpe S, Lightfoot H, et al: A landscape of pharmacogenomic interactions in cancer. Cell. 166:740–754. 2016. View Article : Google Scholar : PubMed/NCBI
13	Teicher BA, Polley E, Kunkel M, Evans D, Silvers T, Delosh R, Laudeman J, Ogle C, Reinhart R, Selby M, et al: Sarcoma cell line screen of oncology drugs and investigational agents identifies patterns associated with gene and microRNA expression. Mol Cancer Ther. 14:2452–2462. 2015. View Article : Google Scholar : PubMed/NCBI
14	Oey H, Daniels M, Relan V, Chee TM, Davidson MR, Yang IA, Ellis JJ, Fong KM, Krause L and Bowman RV: Whole-genome sequencing of human malignant mesothelioma tumours and cell lines. Carcinogenesis. 40:724–734. 2019. View Article : Google Scholar : PubMed/NCBI
15	Relan V, Morrison L, Parsonson K, Clarke BE, Duhig EE, Windsor MN, Matar KS, Naidoo R, Passmore L, McCaul E, et al: Phenotypes and karyotypes of human malignant mesothelioma cell lines. PLoS One. 8:e581322013. View Article : Google Scholar : PubMed/NCBI
16	Conte N, Mason JC, Halmagyi C, Neuhauser S, Mosaku A, Yordanova G, Chatzipli A, Begley DA, Krupke DM, Parkinson H, et al: PDX Finder: A portal for patient-derived tumor xenograft model discovery. Nucleic Acids Res. 47(D1): D1073–D1079. 2019. View Article : Google Scholar : PubMed/NCBI
17	Yoshimatsu Y, Noguchi R, Tsuchiya R, Kito F, Sei A, Sugaya J, Nakagawa M, Yoshida A, Iwata S, Kawai A and Kondo T: Establishment and characterization of NCC-CDS2-C1: A novel patient-derived cell line of CIC-DUX4 sarcoma. Hum Cell. 33:427–436. 2020. View Article : Google Scholar : PubMed/NCBI
18	Bairoch A: The cellosaurus, a cell-line knowledge resource. J Biomol Tech. 29:25–38. 2018. View Article : Google Scholar : PubMed/NCBI
19	Capes-Davis A, Reid YA, Kline MC, Storts DR, Strauss E, Dirks WG, Drexler HG, MacLeod RA, Sykes G, Kohara A, et al: Match criteria for human cell line authentication: Where do we draw the line? Int J Cancer. 132:2510–2519. 2013. View Article : Google Scholar : PubMed/NCBI
20	Noguchi R, Yoshimatsu Y, Ono T, Sei A, Hirabayashi K, Ozawa I, Kikuta K and Kondo T: Establishment and characterization of NCC-PLPS1-C1, a novel patient-derived cell line of pleomorphic liposarcoma. Hum Cell. 34:688–697. 2020. View Article : Google Scholar : PubMed/NCBI
21	Olshen AB, Venkatraman ES, Lucito R and Wigler M: Circular binary segmentation for the analysis of array-based DNA copy number data. Biostatistics. 5:557–572. 2004. View Article : Google Scholar : PubMed/NCBI
22	Venkatraman ES and Olshen AB: A faster circular binary segmentation algorithm for the analysis of array CGH data. Bioinformatics. 23:657–663. 2007. View Article : Google Scholar : PubMed/NCBI
23	Willenbrock H and Fridlyand J: A comparison study: Applying segmentation to array CGH data for downstream analyses. Bioinformatics. 21:4084–4091. 2005. View Article : Google Scholar : PubMed/NCBI
24	Forbes SA, Tang G, Bindal N, Bamford S, Dawson E, Cole C, Kok CY, Jia M, Ewing R, Menzies A, et al: COSMIC (the catalogue of somatic mutations in cancer): A resource to investigate acquired mutations in human cancer. Nucleic Acids Res 38 (Database Issue). D652–D657. 2010. View Article : Google Scholar : PubMed/NCBI
25	Billiau A, Edy VG, Heremans H, Van Damme J, Desmyter J, Georgiades JA and De Somer P: Human interferon: Mass production in a newly established cell line, MG-63. Antimicrob Agents Chemother. 12:11–15. 1977. View Article : Google Scholar : PubMed/NCBI
26	Sikkema AH, Diks SH, den Dunnen WF, ter Elst A, Scherpen FJ, Hoving EW, Ruijtenbeek R, Boender PJ, de Wijn R, Kamps WA, et al: Kinome profiling in pediatric brain tumors as a new approach for target discovery. Cancer Res. 69:5987–5995. 2009. View Article : Google Scholar : PubMed/NCBI
27	Hornbeck PV, Zhang B, Murray B, Kornhauser JM, Latham V and Skrzypek E: PhosphoSitePlus, 2014: Mutations, PTMs and recalibrations. Nucleic Acids Res 43 (Database Issue). D512–D520. 2015. View Article : Google Scholar : PubMed/NCBI
28	UniProt Consortium: UniProt: A worldwide hub of protein knowledge. Nucleic Acids Res. 47(D1): D506–D515. 2019. View Article : Google Scholar : PubMed/NCBI
29	Keshava Prasad TS, Goel R, Kandasamy K, Keerthikumar S, Kumar S, Mathivanan S, Telikicherla D, Raju R, Shafreen B, Venugopal A, et al: Human protein reference database-2009 update. Nucleic Acids Res 37 (Database Issue). D767–D772. 2009. View Article : Google Scholar : PubMed/NCBI
30	van Meerbeeck JP, Baas P, Debruyne C, Groen HJ, Manegold C, Ardizzoni A, Gridelli C, van Marck EA, Lentz M and Giaccone G: A Phase II study of gemcitabine in patients with malignant pleural mesothelioma. European organization for research and treatment of cancer lung cancer cooperative group. Cancer. 85:2577–2582. 1999. View Article : Google Scholar : PubMed/NCBI
31	Zucali PA, Ceresoli GL, Garassino I, De Vincenzo F, Cavina R, Campagnoli E, Cappuzzo F, Salamina S, Soto Parra HJ and Santoro A: Gemcitabine and vinorelbine in pemetrexed-pretreated patients with malignant pleural mesothelioma. Cancer. 112:1555–1561. 2008. View Article : Google Scholar : PubMed/NCBI
32	Zucali PA, Perrino M, Lorenzi E, Ceresoli GL, De Vincenzo F, Simonelli M, Gianoncelli L, De Sanctis R, Giordano L and Santoro A: Vinorelbine in pemetrexed-pretreated patients with malignant pleural mesothelioma. Lung Cancer. 84:265–270. 2014. View Article : Google Scholar : PubMed/NCBI
33	Szulkin A, Nilsonne G, Mundt F, Wasik AM, Souri P, Hjerpe A and Dobra K: Variation in drug sensitivity of malignant mesothelioma cell lines with substantial effects of selenite and bortezomib, highlights need for individualized therapy. PLoS One. 8:e659032013. View Article : Google Scholar : PubMed/NCBI
34	O'Brien ME, Gaafar RM, Popat S, Grossi F, Price A, Talbot DC, Cufer T, Ottensmeier C, Danson S, Pallis A, et al: Phase II study of first-line bortezomib and cisplatin in malignant pleural mesothelioma and prospective validation of progression free survival rate as a primary end-point for mesothelioma clinical trials (European organisation for research and treatment of cancer 08052). Eur J Cancer. 49:2815–2822. 2013. View Article : Google Scholar : PubMed/NCBI
35	Fennell DA, McDowell C, Busacca S, Webb G, Moulton B, Cakana A, O'Byrne KJ, Meerbeeck JV, Donnellan P, McCaffrey J and Baas P: Phase II clinical trial of first or second-line treatment with bortezomib in patients with malignant pleural mesothelioma. J Thorac Oncol. 7:1466–1470. 2012. View Article : Google Scholar : PubMed/NCBI
36	Huang CC, Han CS, Yue XF, Shen CM, Wang SW, Wu FG and Xu B: Cytotoxicity and sister chromatid exchanges induced in vitro by six anticancer drugs developed in the People's Republic of China. J Natl Cancer Inst. 71:841–847. 1983.PubMed/NCBI
37	Kantarjian HM, Keating MJ, Walters RS, Koller CA, McCredie KB and Freireich EJ: Phase II study of low-dose continuous infusion homoharringtonine in refractory acute myelogenous leukemia. Cancer. 63:813–817. 1989. View Article : Google Scholar : PubMed/NCBI
38	Quintás-Cardama A, Kantarjian H, Garcia-Manero G, O'Brien S, Faderl S, Estrov Z, Giles F, Murgo A, Ladie N, Verstovsek S and Cortes J: Phase I/II study of subcutaneous homoharringtonine in patients with chronic myeloid leukemia who have failed prior therapy. Cancer. 109:248–255. 2007. View Article : Google Scholar : PubMed/NCBI
39	Friedberg JW, Sharman J, Sweetenham J, Johnston PB, Vose JM, Lacasce A, Schaefer-Cutillo J, De Vos S, Sinha R, Leonard JP, et al: Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia. Blood. 115:2578–2585. 2010. View Article : Google Scholar : PubMed/NCBI
40	Tsao AS, He D, Saigal B, Liu S, Lee JJ, Bakkannagari S, Ordonez NG, Hong WK, Wistuba I and Johnson FM: Inhibition of c-Src expression and activation in malignant pleural mesothelioma tissues leads to apoptosis, cell cycle arrest, and decreased migration and invasion. Mol Cancer Ther. 6:1962–1972. 2007. View Article : Google Scholar : PubMed/NCBI
41	Xu D, Liang SQ, Yang H, Bruggmann R, Berezowska S, Yang Z, Marti TM, Hall SRR, Gao Y, Kocher GJ, et al: CRISPR screening identifies WEE1 as a combination target for standard chemotherapy in malignant pleural mesothelioma. Mol Cancer Ther. 19:661–672. 2020. View Article : Google Scholar : PubMed/NCBI
42	Dorai T, Kobayashi H, Holland JF and Ohnuma T: Modulation of platelet-derived growth factor-beta mRNA expression and cell growth in a human mesothelioma cell line by a hammerhead ribozyme. Mol Pharmacol. 46:437–444. 1994.PubMed/NCBI
43	Langerak AW, Dirks RP and Versnel MA: Splicing of the platelet-derived-growth-factor A-chain mRNA in human malignant mesothelioma cell lines and regulation of its expression. Eur J Biochem. 208:589–596. 1992. View Article : Google Scholar : PubMed/NCBI
44	Melaiu O, Catalano C, De Santi C, Cipollini M, Figlioli G, Pellè L, Barone E, Evangelista M, Guazzelli A, Boldrini L, et al: Inhibition of the platelet-derived growth factor receptor beta (PDGFRB) using gene silencing, crenolanib besylate, or imatinib mesylate hampers the malignant phenotype of mesothelioma cell lines. Genes Cancer. 8:438–452. 2017. View Article : Google Scholar : PubMed/NCBI
45	Edgar R, Domrachev M and Lash AE: Gene expression omnibus: NCBI gene expression and hybridization array data repository. Nucleic Acids Res. 30:207–210. 2002. View Article : Google Scholar : PubMed/NCBI